Obesity Paradox in Non Valvular Atrial Fibrillation NCT03904329

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Recruiting

Obesity paradox In patient with non valvular atrial fibrillation

Study role of obesity in outcomes of anticoagulation in patients with non valvular atrial fibrillation

Recruitment information / eligibility
Status	Recruiting
Enrollment	1
Est. completion date	October 1, 2023
Est. primary completion date	August 1, 2023
Accepts healthy volunteers	No
Gender	All
Age group	18 Years to 90 Years
Eligibility	Inclusion Criteria: - patients presented with non valvular AF - patients on oral anticoagulant Exclusion Criteria: - valvular AF - Mental illness - History of cerebrovascular stroke - history of bleeding tendency - history of Chronic renal failure

Drug:
• Oral Anticoagulant
Oral tablets of anti coagulations either warfare or NOACs

Locations
Country	Name	City	State
Egypt	Kristen amir	Assiut

Sponsors *(1)*
Lead Sponsor	Collaborator
Assiut University

Egypt,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between obesity and outcomes in non valvular atrial fibrillation	To study effect of obesity in outcomes of non valvular atrial fibrillation regarding the effect of obesity in the outcome of anticoagulants	Sixth months